anidulafungin 50 MG Injection [Eraxis]

What the CMS Formulary Data Shows for anidulafungin 50 MG Injection [Eraxis]

Per the CMS 2026 Part D formulary file, anidulafungin 50 MG Injection [Eraxis] (RxNorm concept RXCUI 1804746, generic name anidulafungin) appears on 19 distinct formulary files spanning 176 Medicare Part D plan offerings - 3.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.5.

Real-world access to anidulafungin 50 MG Injection [Eraxis] depends on utilization management as much as tier placement: 42.1% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 146 Part D beneficiaries filled anidulafungin 50 MG Injection [Eraxis] in 2023, with total plan-and-beneficiary spending of $593,317 and an average per-beneficiary annual cost of $4,063.82. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry anidulafungin 50 MG Injection [Eraxis] today.